Finally, COBAS EGFR mutation test V2 (Roche Molecular Systems, Indianapolis, IN, USA) detects somatic mutations in the EGFR gene from FFPE tumor DNA or plasma ctDNA and is used as a companion diagnostics method for the selection of targeted therapies in lung cancer patients [95]. Here, EGFR is linked to neoplasm.